Principal in a law firm concentrating on corporate law, mergers and acquisitions (M&A), intellectual property licensing, antitrust law, commercial, contracts, employment, credit and loan agreements, corporate governance and Sarbanes-Oxley matters, and SEC '34 Act filings. Extensive turnaround and business-crisis experience.

National health care accreditation organization, with CMS deeming authority for Medicaid and Medicare participation by home health, hospice and durable medical equipment, prosthetics, orthopedics and supplies (DMEPOS) organizations, and pharmacies.

Co-arbitrator in a three-member ICC Paris arbitration involving a major dispute between two large international companies in the United States and Europe pertaining to Swiss law, contractual matters and certain US regulatory requirements, from inception through final award.

Joined the management of a publicly traded pharmaceutical company on an interim basis to act as general counsel until it could hire a permanent general counsel. During the year that followed, managed the legal activities of the core leadership team, together with the CEO and CFO, for a series of critical turnaround actions, including divestiture of its generic pharmaceutical business and assets; successful resolution of the risk of federal HHS OIG healthcare exclusion; obtaining of a critical $120 million credit facility; successful placement of a PIPE private placement of equity; successful placement of a $225 million secured bond offering; bringing the Company's SEC '34 Act filings current; and successful resolution of numerous litigation disputes and exposure.

Principal in a law firm providing a broad range of corporate, commercial and business legal services to companies of all sizes, from startups to publicly-owned corporations. Extensive experience in providing expertise ranging from complex and substantial mergers and acquisitions, to incorporating new companies, to intellectual property licensing transactions, to contract negotiation, to the handling and resolution of commercial disputes, to employment issues, and to the proper preparation of SEC '34 Act filings.

General Counsel for a publicly traded $600 million branded and generic specialty pharmaceutical company active in women's health, cardiovascular, and pain management. Directed the Company's litigation practice, including its patent, Lanham Act, product liability, Hatch-Waxman, Medicaid pharmaceutical pricing, and general commercial litigation and arbitration.

General Counsel and Secretary to the Board of Directors for a publicly traded $240 million company manufacturing and selling drugs in pain management and critical care and providing drug development services to the worldwide pharmaceutical industry. Led the legal and patent department and, prior to mid-2005, AAI’s environmental, health and safety (EH&S) functions and personnel. Directed all patent and general litigation of the Company, as well as all antitrust matters and SEC compliance and filings. Lead or co-lead negotiator in numerous acquisitions, technology and intellectual property licensing agreements, and contemplated mergers, working in a team with the company’s President. Created and implemented the company’s compliance program, including its Code of Conduct and compliance with Sarbanes-Oxley, antitrust, and healthcare fraud and abuse. Led the legal efforts in 2005-2006 to successfully take the company through Chapter 11 and reorganize it as a drug development services company and divest its pharmaceutical assets and business, emerging as a privately-held company in March 2006.

Member, Board of Directors, of an independent oil and gas exploration and production company in Colorado.

Brought into Siemens Medical Systems, a $1.7 billion manufacturer and distributor of MRI, CT, X-ray, oncology, angiographic and other medical diagnostic and therapy equipment, to turn around its troubled FDA regulatory and quality systems compliance program. Restored the company’s credibility with the U.S. Food & Drug Administration and persuaded FDA to lift its “permanent” Consent Decree after only 3 years. Led the regulatory turnaround efforts to reopen 3 businesses shut down by an FDA Consent Decree for more than a year. Managed 25 FDA regulatory, OSHA, EPA and quality systems professionals, with functional oversight over another 100 personnel across 7 business units in Siemens Medical.

Acted as general counsel to multiple Siemens operating companies in the eastern U.S. Managed a team of 16 attorneys providing general legal services to all Siemens operating companies in the eastern United States, including its medical equipment, automotive electronics, automation, computer, and lighting companies, with aggregate U.S. revenues of $3 billion. Managed a team of 11 specialist attorneys providing legal services for all U.S. Siemens operating companies with respect to antitrust, mergers, acquisitions, project finance, environmental, labor, employment, and litigation matters. Acted as lead antitrust expert for all Siemens’ U.S. companies.Acted as Siemens’ lead acquisition and transactional counsel between 1986 and 1993, directly and through managing its team of M&A attorneys. Personally negotiated and closed 10 major and numerous smaller U.S. and international acquisitions, divestitures and joint ventures, with aggregate transaction values of $3.4 billion, including major acquisitions of companies and businesses in lighting products, automotive electronics, telecommunications equipment, and industrial automation.Board Secretary - Siemens-Bendix Automotive Electronics and Siemens Industrial Automation.

Corporate and antitrust lawyer for numerous U.S. and international clients, including in Germany, Canada, France, the United Kingdom and South Africa. Industries included the electronics, beer, aluminum, cement, paper, supermarket, diamond gemstones, and waste management industries.Corporate work included general corporate, transactional (including mergers, acquisitions, joint ventures, and leveraged buyouts), licensing, credit and loan agreements, and regulatory matters. Antitrust work included antitrust evaluation and structuring of mergers and acquisitions, extensive interactions with the Federal Trade Commission and the Antitrust Division of the U.S. Department of Justice, grand jury investigations, and antitrust evaluation and structuring of commercial conduct.